Search Results
Your search for The ASCO ,The ASCO matches 20588 pages
Showing 7451 - 7500Diagnostic and Treatment Technology Disparities Among Patients With Colorectal Cancer
In a study published by Frankenfeld et al in Cancer Epidemiology, researchers found racial disparities in how the presence of cancer-related diagnostic and treatment technology is related to colorectal cancer patient outcomes in Georgia. The findings suggest that the hospital capacity and...
Proteomic Analysis of Endometrial Cancer
A comprehensive molecular study of endometrial cancer published by Dou et al in Cell has further defined the contributions of key genes and proteins to the disease. The overview suggests new treatment approaches that could be tailored for each patient, as well as potential biologic targets for...
HSD3B1 Genotype and Its Effect on Castration Resistance and Overall Survival in Prostate Cancer
As reported in JAMA Oncology, Nima Sharifi, MD, and colleagues have found that the adrenal-permissive HSD3B1 genotype is associated with earlier onset of castration resistance and poorer overall survival in men with low-volume metastatic prostate cancer. As noted by the investigators, the...
Syed A. Hussain, MD, on Muscle-Invasive Bladder Cancer: NEO-BLADE Trial of Nintedanib Plus Chemotherapy
Syed A. Hussain, MD, of the University of Sheffield, discusses phase II findings comparing nintedanib or placebo in combination with gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer. The data showed that adding nintedanib was safe and well tolerated, with a significant...
Jonathan E. Rosenberg, MD, on Locally Advanced or Metastatic Urothelial Carcinoma: Enfortumab Vedotin Plus Pembrolizumab
Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses study results which showed that, in first-line cisplatin-ineligible patients with metastatic urothelial carcinoma, enfortumab vedotin/pembrolizumab demonstrated activity and durability, with a manageable safety profile...
PRH/HHEX Transcription Factor as a Treatment Target in Patients With Cholangiocarcinoma
Treatment of patients with cholangiocarcinoma could be improved by tailoring medication to the levels of a key protein in people with the disease, according to new research published by Kitchen et al in Cancer Research. Researchers have discovered that the proline-rich homeodomain...
States With Highest Rates of Cutaneous Melanoma Due to Ultraviolet Exposure
A new study found a wide state-by-state variation in rates of melanoma caused by ultraviolet (UV) exposure, with highest rates in several states on the east and west coasts (including Hawaii), but also a few landlocked states (including Utah, Vermont, and Minnesota). The report, published by Islami ...
ASCO/CCO Update Guideline for Selecting Systemic Treatment in Stage IV NSCLC Without Driver Mutations
ASCO and Cancer Care Ontario (CCO) have published an update to a joint guideline on systemic therapy for stage IV non–small cell lung cancer (NSCLC) without driver mutations.1 “The treatment of stage IV NSCLC has become increasingly more complicated, and, with the advent of immunotherapy and the...
Two Novel Pegylated Agents Fail in Metastatic Pancreatic Cancer
Two novel treatments once thought to hold promise in the treatment of metastatic pancreatic cancer have not proved to be effective in phase III trials, investigators reported at the 2020 Gastrointestinal Cancers Symposium. When combined with standard chemotherapy, a pegylated form of human...
H pylori Infection and Gastric Cancer Risk
First, we’ll discuss a Korean trial that looked at the role of H pylori infection and gastric cancer risk. Next, we’ll turn to a modeling study that examined HPV vaccination and cervical cancer incidence in low-income and lower–middle-income countries. Last this week, we’ll look at data presented...
FDA Pipeline: Priority Reviews in Lymphoma, Lung Cancer, GIST, and Breast Cancer
This week, the U.S. Food and Drug Administration (FDA) granted Priority Review to agents in lymphoma, lung cancer, gastrointestinal stromal tumors, and breast cancer, and granted Fast Track designation to a first-in-class radioenhancer hafnium oxide nanoparticle in head and neck cancer. Priority...
2020 GU Cancers Symposium: Talazoparib for Pretreated Patients With Metastatic Castration-Resistant Prostate Cancer
According to results from a phase II trial presented by Johann S. de Bono, MD, PhD, and colleagues at the 2020 Genitourinary (GU) Cancers Symposium (Abstract 119), treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib showed antitumor activity in patients with metastatic...
2020 GU Cancers Symposium: Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer
In patients with metastatic urothelial carcinoma, platinum chemotherapy is the standard of care in the first-line setting; however, for patients who are ineligible for platinum treatment, the alternative standard—gemcitabine plus carboplatin—can be poorly tolerated and have limited durability and...
Ivana Sestak, PhD, on Clinical Treatment Score From TAILORx: Predicting Distant Breast Cancer Recurrence
Ivana Sestak, PhD, of Queen Mary University of London and the Centre for Cancer Prevention, discusses study findings that confirm the prognostic ability of the Clinical Treatment Score at 5 years (CTS5) for late distant recurrence, specifically for patients older than 50 years and/or for those...
Hongchao Pan, PhD, on an Update on 5 Years of Endocrine Therapy for Early Breast Cancer
Hongchao Pan, PhD, of the University of Oxford, discusses an analysis of 86,000 women in the Early Breast Cancer Trialists’ Collaborative Group database, which showed that the risk of distant recurrence 20 years after a diagnosis of node-negative, estrogen receptor–negative early-stage breast...
Study Finds ‘Bridge’ to CAR T-Cell Therapy May Be Detrimental to Survival
The use of bridging therapy before treatment with axicabtagene ciloleucel was associated with worse overall survival in univariate, multivariate, and propensity score–matched analyses performed on data from the U.S. Lymphoma CAR T Consortium, investigators reported at the 2019 American Society of...
2020 GU Cancers Symposium: Oral HIF2A Inhibitor for Advanced Clear Cell Renal Cell Carcinoma
A novel, first-in-class, small molecule, hypoxia-inducible factor 2 alpha (HIF2A) inhibitor showed single-agent activity in heavily pretreated patients with metastatic clear cell renal cell carcinoma. These results from a phase I/II study will be presented by Toni Choueiri, MD, and colleagues at...
Therapy-Associated Polyposis in Survivors of Childhood Cancer
A report published by Biller et al in Cancer Prevention Research provides new details about a recently discovered condition in which childhood cancer survivors develop numerous colorectal polyps, despite not having a hereditary susceptibility to the condition. The condition—known as...
Jarrett Failing, MD, on Human Leukocyte Antigen Expression in NSCLC With Brain Metastases
Jarrett Failing, MD, of the Mayo Clinic, discusses his study data, which show some agreement between the expression of human leukocyte antigens in primary non–small cell lung cancer with brain metastasis. His findings may have some bearing on resistance to immune checkpoint inhibitors (Abstract 43).
John N. Lukens, MD, on Advanced Melanoma: Antibiotics, Survival, and Colitis in Patients Receiving Immunotherapy
John N. Lukens, MD, of the Hospital of the University of Pennsylvania, discusses his finding that taking antibiotics within 3 months of starting treatment with immune checkpoint inhibitors may lead to inferior overall survival in patients with stage III or IV melanoma. The antibiotics were also...
Christopher B. Cole, MD, PhD, on Ovarian Cancer: First-in-Human Study of Interferon-Activated Autologous Monocytes
Christopher B. Cole, MD, PhD, of the National Cancer Institute, discusses findings from a phase I study of intraperitoneal monocytes activated by interferons alpha and gamma in patients with ovarian cancer. Two of 11 patients had a partial response and 5 of 11 had stable disease; ongoing efforts...
Kevin Tyan on Colitis Induced by Immune Checkpoint Inhibitors: Potential Preventive Strategy
Kevin Tyan, of Kinnos, and currently a medical school student at Harvard University, discusses his study findings, which showed that patients with melanoma who are treated with immunotherapy had a significantly lower risk of developing colitis if they also took vitamin D ( Abstract 89).
Jacob J. Adashek, DO, on Immunoregulatory Molecules, Cancer Genes, and Therapeutic Insights
Jacob J. Adashek, DO, of the University of South Florida and Moffitt Cancer Center, discusses data on combining immunoregulatory inhibition and targeted gene therapy, which may offer patients better outcomes (Abstract 10).
Martin McCarter, MD, on Refinement of Surgical Treatment: Expert Perspective on ASCO’s 2020 Advance of the Year
Martin McCarter, MD, of the University of Colorado Denver, discusses the recent strides in surgical oncology, how the role of surgery has changed, and what lies ahead for this staple of cancer therapy.
Philippa G. Corrie, PhD, on Patient Outcomes in Melanoma After Immune Checkpoint Inhibition
Philippa G. Corrie, PhD, of Cambridge University Hospitals NHS Foundation Trust, discusses a review of 2,322 patients with metastatic melanoma receiving first-line immune checkpoint inhibitors as standard of care in England between 2014 and 2018 (Abstract 55).
Luis I. Ruffolo, MD, on Pancreatic Cancer: Augmenting Immunotherapy With Antibody Blockade of Semaphorin 4D
Luis I. Ruffolo, MD, of the University of Rochester, discusses preclinical studies showing that semaphorin 4D blockade may sensitize pancreatic tumors to chemoimmunotherapy combinations (Abstract 26).
Dario Vignali, PhD, on Immune Resistance Mechanisms in Cancer
Dario Vignali, PhD, of the University of Pittsburgh and UPMC Hillman Cancer Center, summarizes his Keynote Address, which covered what drives systemic immune dysfunction in patients with cancer, what promotes inhibitory receptor expression, and what limits the persistence of antigen-specific T...
Elizabeth A. Mittendorf, MD, PhD, on Mobilizing the Immune System to Treat Select Solid Tumors
Elizabeth A. Mittendorf, MD, PhD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, summarizes a session she co-chaired on utilizing the immune system in neoadjuvant trials to treat melanoma, breast, and lung cancers.
Expert Point of View: Marcia Cruz-Correa, MD, PhD
Marcia Cruz-Correa, MD, PhD, Professor of Medicine at the University of Puerto Rico and Adjunct Professor of Surgical Oncology at The University of Texas MD Anderson Cancer Center, congratulated the investigators on the conduct of the PANGEA trial and the outcomes it achieved for patients. “When...
Do Gay and Bisexual Men Have an Increased Risk of Developing Skin Cancer?
In the largest study to date of skin cancer rates among individuals who identify as gay, lesbian, or bisexual, investigators from Brigham and Women's Hospital reported important differences in skin cancer prevalence among sexual minorities. Rates of skin cancer were higher among gay and bisexual...
Dengue Virus Infection May Increase Risk of Developing Leukemia
Compared to individuals without a history of dengue virus infection, those previously infected with the virus had over twice the risk of developing leukemia, with the highest risk occurring between 3 and 6 years after infection. The results of a study conducted in Taiwan were published by Chien et...
A Breast Cancer Clinical Trial Includes a Meal Delivery Service in ‘Prescribing a Diet to Conquer Cancer’
Your Stories, the podcast series from Conquer Cancer, the ASCO Foundation®, kicks off its third season with a conversation between oncologist Neil Iyengar, MD, and nutrition advocate Nadja Pinnavaia, PhD. The pair have joined forces to help reduce the risk of cancer and share the latest research...
Congress Increases Federal Investment in Cancer Research, Raises Tobacco Purchasing Age
President Trump recently signed a bill that funds the federal government, including the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the U.S. Food and Drug Administration (FDA), for Fiscal Year (FY) 2020. Importantly, the bill also raises the purchasing age of...
ASCO Analysis Demonstrates Need to Harmonize Disclosure Policies Across Medicine
An analysis by ASCO shows substantial discordance between disclosures to ASCO and to Open Payments, confirming the need for consistent and simpler financial disclosure systems in medicine.1 The paper examined disclosures from 93 presenters at the 2018 ASCO Annual Meeting and 70 published authors in ...
Over 30 Oncology Practices Achieve ASCO’s QOPI® Certification in Fourth Quarter of 2019
Thirty-three practices in three countries elevated their standard of care and achieved Quality Oncology Practice Initiative (QOPI®) certification or recertification in the fourth quarter of 2019. ASCO commends these practices, which have demonstrated their commitment to providing the...
Join the Conquerors Community
Monthly giving is an efficient and effective way to help conquer cancer all year long. Monthly gifts to Conquer Cancer, the ASCO Foundation®, are processed automatically, which helps reduce costs and allows your donation to have the greatest possible impact in funding the research advancing the...
Clinical Cancer Advances 2020: ASCO Names Advance of the Year, Issues Research Priorities for the Cancer Community
In the release of its annual report on progress against cancer, Clinical Cancer Advances 2020, ASCO recognized progress in the refinement of the surgical treatment of cancer as the Advance of the Year. In particular, the emergence of novel systemic therapies—combined in new and better ways—has...
Overcoming Barriers to Alleviating Cancer-Related Pain in Ethiopia
According to the World Health Organization (WHO), approximately 70% of deaths from cancer occur in low- and middle-income countries, where late-stage presentation and inaccessibility to diagnosis and treatment are common.1 In the sub-Saharan African country of Ethiopia, cancer is becoming an...
ASCO-SITC 2020: Ilixadencel/Sunitinib vs Sunitinib Alone in Synchronous Metastatic Kidney Cancer
In a study presented by Lindskog et al at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium (Abstract 11), researchers found ilixadencel, a cell-based allogeneic off-the-shelf product, in combination with sunitinib produced a higher objective response rate than sunitinib alone in patients with...
Five-Year Patient-Reported Outcomes for Various Prostate Cancer Treatments
A 5-year follow-up study of more than 2,000 U.S. men who received prostate cancer treatment—radiation, surgery, or active surveillance—in patients of all ages and ethnicities is creating a road map for the future regarding long-term bowel, bladder, and sexual function in order to clarify...
Genetic Mutations in Donor Stem Cells May Affect Hematopoietic Transplant Recipients
A new study on hematopoietic stem cell transplantation from Washington University School of Medicine in St. Louis suggests that extremely rare, harmful genetic mutations present in healthy donors’ stem cells—though not causing health problems in the donors—may be passed on to patients with cancer...
ASCO-SITC 2020: Low Incidence of Nivolumab-Induced Radiation Recall Pneumonitis Among Patients With NSCLC
A multicenter retrospective study investigating the incidence of pneumonitis and the incidence, risk factors, and clinical characteristics of radiation recall pneumonitis in patients with non–small cell lung cancer (NSCLC) who had received nivolumab found the incidence of radiation recall...
University of Maryland Greenebaum Comprehensive Cancer Center Joins Big Ten Cancer Research Consortium
The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) has joined the Big Ten Cancer Research Consortium. The Big Ten Cancer Research Consortium was created in 2013 to transform the conduct of cancer research through collaborative, hypothesis-driven, highly...
Fox Chase Cancer Center Certified Under ASCO’s Quality Oncology Practice Initiative
Fox Chase Cancer Center has been recognized under ASCO’s Quality Oncology Practice Initiative (QOPI®) by the QOPI Certification Program LLC as successfully completing a 3-year certification for oncology practices that meet nationally recognized standards for quality and safety in cancer care. “Fox...
Stand Up To Cancer Announces Initiative to Increase Diversity in Clinical Trials
Stand Up To Cancer (SU2C) recently announced an initiative to increase minority representation in cancer clinical trials. All future SU2C-supported research grant proposals will now be required to include and address crucial issues related to recruitment and retention of patients from ethnic groups ...
ASH Presents 2019 Joanne Levy, MD, Memorial Award for Outstanding Achievement to Nicholas J. Short, MD
Nicholas J. Short, MD, of The University of Texas MD Anderson Cancer Center, Houston, received the 2019 Joanne Levy, MD, Memorial Award for Outstanding Achievement at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando. This annual award (which includes a...
Urology of Virginia Welcomes New Chief Medical Officer Joshua Langston, MD
Urology of Virginia has announced the transition of Joshua Langston, MD, to the role of Chief Medical Officer for the organization. He assumed this new position on January 1 and will continue the legacy of patient care, organizational guidance, innovation, and service of his predecessor, Dr. Edwin...
Susan Sturgeon, MPH, DrPH, Receives NIH Grant to Study Environmental Exposure on Breast Cancer Risk
University of Massachusetts Amherst (UMass Amherst) cancer epidemiologist, and Professor of Biostatistics and Epidemiology in the School of Public Health and Health Sciences, Susan Sturgeon, MPH, DrPH, has received a $462,000 grant from the National Institutes of Health (NIH) to expand her research ...
Fox Chase Cancer Center Welcomes Claudia J. Kasales, MD, MHA, FACR
Fox Chase Cancer Center has announced the hiring of Claudia J. Kasales, MD, MHA, FACR, who will join the Department of Diagnostic Imaging as Professor on the academic clinician track. Dr. Kasales began work at Fox Chase on February 1, 2020. Dr. Kasales comes to Fox Chase from Penn State Health...
Is There a Future Role for Secondary Cytoreductive Surgery in the Treatment of Recurrent Ovarian Cancer?
In a recent issue of The New England Journal of Medicine, Coleman et al released the results from the GOG-0213 trial, a multicenter, randomized prospective trial that compared secondary cytoreduction followed by chemotherapy with chemotherapy alone in women with platinum-sensitive recurrent ovarian ...
